FRI0302 Tocilizumab, DMARDS and Glucocorticoids in Rheumatoid Arthritis – Interim Analysis of the German Non-Interventional Study Ichiban

Background The ICHIBAN study collects routine clinical data to evaluate the effectiveness and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in real world practice over a period of 2 years. Methods The start of this prospective, non-interventional study was in February 2010. The target recruitment is 4000 patients. Therapeutic data, relevant progression parameters as well as activity scores and adverse events are recorded. Results As of 1st December 2013, baseline data for 2373 patients with a mean age was 56.4 years were available. 75.9% of these patients were female and the median duration of RA was 7.4 years. The total TCZ exposure was 4084.8 patient years. In 589 patients the duration of observation has reached the intended period of 2 years, or treatment was interrupted or changed before and analysed according to LOCF method. 73.9% were pre-treated with TNF-alpha inhibitors, 24.6% exclusively with synthetic DMARDs. The mean baseline DAS28 of the 589 patients was 5.6. At the end of observation 36.2% achieved DAS28-ESR remission (